Pacific Biosciences of California (PACB) vs QuidelOrtho (QDEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed QuidelOrtho (QDEL) over the past year, gaining 52.3% versus a loss of 55.6%. Over five years, PACB leads with a -88.8% price change compared with -90.4% for QDEL. QuidelOrtho is the larger company by market cap ($851.0 million vs $714.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PACB | QDEL |
|---|---|---|
| Share price | $2.30 | $12.41 |
| Market cap | $714.91M | $851.02M |
| 1-day change | -15.44% | +0.81% |
| YTD return | +22.99% | -56.90% |
| 1-year return | +52.32% | -55.58% |
| 5-year return | -88.85% | -90.40% |
| Forward P/E | — | 8.61 |
| EPS (TTM) | $-0.43 | $-15.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.44 | $35.58 |
| 52-week low | $1.07 | $9.92 |
| Distance from 52-week high | -33.14% | -65.12% |
| Analyst consensus | buy | hold |
| Avg. price target upside | -6.09% | +18.21% |
| Average volume | 10.10M | 1.49M |
| Shares outstanding | 310.83M | 68.58M |
| Employees | 485 | 6,500 |
| Sector | Industrials | Health Care |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PACB has outperformed QDEL by 107.9 percentage points over the past year.
- The two companies sit in different sectors: Pacific Biosciences of California in Industrials and QuidelOrtho in Health Care.
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
About QuidelOrtho
QDEL stock →QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees
PACB vs QDEL FAQ
Which is bigger, Pacific Biosciences of California or QuidelOrtho?
QuidelOrtho (QDEL) is larger, with a market capitalization of $851.02M compared with $714.91M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, PACB or QDEL?
PACB returned +52.32% over the past 12 months, compared with -55.58% for QDEL (price return, excluding dividends). Past performance does not predict future results.
Are Pacific Biosciences of California and QuidelOrtho in the same industry?
No. Pacific Biosciences of California is in the Industrials sector, while QuidelOrtho is in Health Care.